In a report released today, Yaron Werber from Cowen & Co. maintained a Buy rating on Rocket Pharmaceuticals Inc (RCKT). The company’s shares opened today at $18.27.
According to TipRanks.com, Werber is a 5-star analyst with an average return of 14.7% and a 63.0% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Unum Therapeutics Inc, and Acceleron Pharma.
Rocket Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $39, an 113.5% upside from current levels. In a report issued on April 30, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Based on Rocket Pharmaceuticals Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $27.32 million. In comparison, last year the company had a GAAP net loss of $15.34 million.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RCKT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms.
